



Published in final edited form as:

Prog Nucl Magn Reson Spectrosc. 2017 November ; 102-103: 32–42. doi:10.1016/j.pnmrs.2017.05.002.

Biomolecular MRI Reporters: evolution of new mechanisms

Arnab Mukherjee¹, Hunter C. Davis¹, Pradeep Ramesh², George J. Lu¹, and Mikhail G. Shapiro¹


¹Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125, USA

²Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA 91125, USA

Abstract

Magnetic resonance imaging (MRI) is a powerful technique for observing the function of specific cells and molecules inside living organisms. However, compared to optical microscopy, in which fluorescent protein reporters are available to visualize hundreds of cellular functions ranging from gene expression and chemical signaling to biomechanics, to date relatively few such reporters are available for MRI. Efforts to develop MRI-detectable biomolecules have mainly focused on proteins containing or transporting paramagnetic metals for T_1 and T_2 relaxation enhancement or large numbers of exchangeable protons for chemical exchange saturation transfer. While these pioneering developments established several key uses of biomolecular MRI, such as imaging of gene expression and functional biosensing, they also revealed that low molecular sensitivity poses a major challenge for broader adoption in biology and medicine. Recently, new classes of biomolecular reporters have been developed on alternative contrast mechanisms, including enhancement of spin diffusivity, interactions with hyperpolarized nuclei, and modulation of blood flow. These novel reporters promise to improve sensitivity and enable new forms of multiplexed and functional imaging.

Graphical abstract



*Correspondence should be addressed to MGS: mikhail@caltech.edu, Phone: 626-395-8588, 1200 E. California Blvd, MC 210-41, Pasadena, CA 91125.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

COMPETING INTERESTS

The authors declare no competing financial interests.

Keywords

Magnetic resonance imaging (MRI); contrast agents; biomolecular reporters; diffusion; hyperpolarization

1. Introduction

The ability to image the function of specific cells and molecules within the context of living mammalian organisms is critical for basic biological studies and the development of cellular and genetic therapeutics. Magnetic resonance imaging (MRI) is ideally suited to provide this capability due to its ability to image whole organs and animals non-invasively with high spatial and temporal resolution. However, unlike optical imaging, which has access to a multitude of biomolecular reporters to visualize specific aspects of cellular function, MRI is still in its infancy with regard to its repertoire of biomolecular tools. Over the past 20 years, efforts to develop such tools have primarily focused on biomolecules embodying the properties of synthetic contrast agents, such as paramagnetic ions, superparamagnetic nanoparticles, and chemical exchange substrates, or on causing the accumulation of these synthetic agents in cells, thereby altering the magnetic resonance signal of water protons or other nuclei in their vicinity. These biomolecular reporters have enabled the visualization of previously invisible processes using MRI, such as gene expression, cell migration, and neurotransmission. In addition, they have enabled the use of advanced protein engineering techniques, including directed evolution, to develop dynamic sensors capable of transducing time-varying biochemical signals into MRI contrast changes for real-time functional imaging. Despite these advances, the broader adoption of these technologies by the biomedical community has been hindered by important limitations of these reporters, including their relatively low molecular sensitivity and requirement of metal or synthetic cofactors.

Recently, new biomolecular contrast mechanisms have been introduced that attempt to overcome these limitations, including proteins that act on hyperpolarized nuclei, alter water transport and modify hemodynamics. Notably, some of these new mechanisms are uniquely enabled by biomolecules; that is, they would be impossible or difficult to implement with synthetic agents. The goal of this review is to briefly describe the new classes of biomolecular reporters, place them within the quantitative context of existing contrast mechanisms, and provide an outlook for future developments.

2. Quantitative framework

A key focus of this review is the molecular sensitivity of biomolecular reporters, which we define as the minimal concentration of the reporter that must be present in a voxel to achieve an acceptable level of contrast. While this depends on several factors, including field strength, the overall signal-to-noise ratio (SNR) and the properties of background tissue, we will examine performance under “typical” conditions for conventional small animal ^1H imaging – the primary arena for biomolecular reporter development. Given an SNR of 400 (corresponding to a typical spin echo-based image acquisition sequence at 7 T with 10 averages and an isotropic voxel size of 300 μm , adapted from [1]), a reporter would have to

increase or decrease the signal in a voxel by 1.25% to achieve a contrast-to-noise ratio (CNR) of 5 (*i.e.* 1.25% of 400). This CNR is sufficient to detect reporter-based contrast relative to tissue [2]. The minimal reporter concentration needed to achieve this CNR will serve as our basis for comparing the reporter classes described in the following sections and shown in Table 1. Given the wide range of molecular weights encompassed by biomolecular MRI reporters, as well as the inherent dependence of certain contrast mechanisms on molecular size, both molar and mass-based estimates are useful for reporter comparison. Hence, in addition to asking “how many molecules must a cell make” to produce visible contrast (in μM), we also ask “how much total protein mass must a cell make” for this purpose (in $\mu\text{g/mL}$). Calculations are further explained in the Appendix.

3. Established Mechanisms of Biomolecular MRI: T_1 , T_2 , CEST, Accumulation and Activation

We start by briefly describing the established classes of biomolecular MRI reporters as background for our discussion of new mechanisms. Interested readers may also consult several excellent reviews [3–8].

3.1. T_1 Reporters

Biomolecular T_1 agents are typically metalloproteins containing iron or manganese cofactors [9–11], which produce relaxation enhancement via a predominantly inner-sphere dipole-dipole mechanism, achieving relaxivity (r_{CA} as defined in Eq. A4 and Table 3 of the Appendix) on the order of single $\text{mM}^{-1} \text{s}^{-1}$ (Fig. 1a). In addition to acting as reporters, metalloproteins can be engineered as molecular sensors, wherein the binding of specific ligands occludes water coordination to the metal ion, resulting in reduced relaxivity. For example, the bacterial cytochrome P450-BM3 contains a heme-bound Fe(III) atom, which produces T_1 contrast with a relaxivity of $1.4 \text{ mM}^{-1} \text{ s}^{-1}$ at 4.7 T. A catalytically-inactive version of this protein was engineered by Shapiro *et al.* using directed evolution to bind the neurotransmitter dopamine and thereby act as a sensor of this neurotransmitter [9]. This sensor and its derivatives have been applied to studying dopamine and serotonin release and reuptake in rodent brains [12, 13].

A significant limitation of existing biomolecular T_1 reporters and sensors is their modest relaxivity, in the range of $1\text{--}2 \text{ mM}^{-1} \text{ s}^{-1}$. For a 1.25% change in signal in a T_1 -weighted image (with a background T_1 of 1.5 s), $\sim 14 \mu\text{M}$ concentration of the reporter ($\sim 700 \mu\text{g/ml}$ for a 50 kDa protein such as the dopamine sensor [9]) is needed to produce the required 0.01 s^{-1} relaxation enhancement. This concentration may be difficult to achieve through heterologous expression, especially given the need to load the protein with metal ions and/or additional co-factors such as heme groups. Nevertheless, the ability to engineer these proteins as functional sensors has made them useful as injectable imaging agents that are expressed and purified separately.

Efforts to improve relaxivity have focused on identifying proteins with higher-spin metals, including Mn^{2+} [10], and exchanging natural metals with higher-spin alternatives including Mn^{2+} and Gd^{3+} [14, 15]. In theory, if appropriate proteins can be engineered, and issues

with metal bioavailability can be solved, the molecular sensitivity could improve, especially for imaging conducted at lower field strengths [16].

3.2. T₂ Reporters

One of the first biomolecular MRI reporters to be used in mammals was ferritin, an iron storage protein that biomineralizes a ferrihydrite core with up to 4,500 iron atoms inside a 12 nm diameter protein shell (Fig. 1b). The ferritin core is magnetic, allowing the protein to produce T₂ or T₂* contrast, although a theoretical understanding of this contrast mechanism is incomplete [17]. Since its development as a reporter, ferritin has been used in several studies to monitor cell migration or gene expression. In addition, ferritin-based sensors have been engineered to produce enhanced T₂ relaxation in response to analytes such as protein kinase A through a clustering mechanism [18]. The quantitative sensitivity of ferritin depends on its loading level, which is typically ~ 2,500 iron atoms per particle, which provide a relaxivity at 7 T of 1.28 mM⁻¹ s⁻¹ in terms of iron or 3,000 mM⁻¹ s⁻¹ in terms of ferritin particles [19]. To produce a 1.25% signal change on top of a typical 50 ms tissue T₂, a relaxation enhancement of ~ 0.25 s⁻¹ requires a relatively low ferritin particle concentration of 84 nM and a protein mass of ~ 40 µg/mL (given a total molecular weight of ~ 480 kDa for ferritin). However, a significant challenge with T₂ reporters is the specificity of their contrast, since multiple sources of magnetic susceptibility differences, such as blood and air compartments, exist inside tissues [20, 21]. These can confound the assignment of hypointense regions on T₂ images. Signal changes significantly larger than 1.25%, and concomitantly higher concentrations of ferritin, may therefore be required to confidently locate the reporter in certain tissues. This may be challenging, since even 84 nM ferritin already represents an iron concentration of ~ 210 µM, which may not be achievable in all tissues. Additionally, the relaxivity of ferritin and other magnetic materials in tissues has a strong dependence on their subcellular spatial arrangement [22].

Significant room for improvement exists in the sensitivity of biomolecular T₂ reporters when they are compared to synthetic iron oxide nanoparticles and biogenic magnetite from magnetotactic bacteria, which have relaxivities on the order of 100 mM⁻¹ s⁻¹. Indeed, purified ferritin loaded with a superparamagnetic iron core *in vitro* under high temperature and alkaline pH, has a more than 100-fold stronger per-iron relaxivity compared to natural ferritin [23]. However, magnetite/maghemite mineralization in mammalian cells or bacteria, other than magnetotactic bacteria or their close relatives [24], has not been reported, and is challenging due to the strict chemical conditions required for such mineralization. Recent attempts to engineer or evolve ferritin have resulted in particles with somewhat stronger MRI contrast, but no evidence of minerals other than ferrihydrite [25–27]. Other biomolecular T₂ reporters that may interest the reader include hemoglobin [28], tyrosinase [29], and mms6 [30].

3.3. Chemical Exchange Saturation Transfer (CEST) Reporters

Another pioneering form of biomolecular MRI, CEST imaging, takes advantage of the abundance of exchangeable protons on the protein backbone and amino acid side chains (Fig. 1c). By applying radiofrequency saturation at the chemical shift of these protons while they exchange with surrounding water, a fraction of the aqueous proton pool becomes

depolarized, thereby producing contrast. Although this exchange also takes place with endogenous proteins present in tissue, the overexpression of proteins containing large numbers of proton-exchangeable amino acids, such as lysine-rich protein or human protamine 1, can generate significant contrast above background [31–33]. Molecular sensitivity is further aided by the fact that each protein contains hundreds of exchangeable protons. An additional feature of biomolecular CEST reporters is their potential for multiplexed imaging, which can be accomplished using poly-amino acids (such as poly-lysine and poly-arginine) that have exchangeable proton signals at specific chemical shifts [34].

The molecular sensitivity of CEST reporters is limited by the proton exchange rate, which must be slow compared to their chemical shift difference from water, ω , for efficient saturation transfer [35–37], but faster than T_1 or T_2 relaxation. With a typical exchange rate on the order of 1 kHz, 200 exchangeable groups, and a saturation time comparable to T_1 , the 1.25% signal change detection limit under ideal saturation conditions should be on the order of 2.5 μM (or $\sim 80 \mu\text{g/mL}$ protein assuming a molecular weight of 32 kDa as for poly-lysine [33]). However, in *in vivo* applications, biomolecular CEST agents must also overcome background CEST contrast from endogenous proteins, making their detection at such low concentrations more difficult. Despite this limitation, protein-based CEST reporters have been used in several *in vivo* applications, and innovative pulse sequences and processing schemes have been developed to help maximize reporter-specific contrast [38–40].

3.4. Accumulation or Activation Reporters

In addition to biomolecular MRI reporters that act directly on nuclei, it is also possible to generate MRI contrast indirectly via biomolecules that locally trap or activate exogenous contrast agents (Fig. 1d). This mechanism represents a form of amplification because each biomolecular reporter can transport or chemically modify multiple contrast agents, each of which then interacts with nuclei. Indeed, the earliest examples of biomolecular reporters for magnetic resonance belong to this category. In 1990, Koretsky *et al.* showed that overexpression of creatine kinase led to accumulation of phosphocreatine, which could be detected with ^{31}P NMR [41]. Another early example was beta galactosidase, which cleaves a sugar group from a specially designed Gd^{3+} chelate, thereby unblocking water accessibility and increasing T_1 relaxivity [42]. Other reporters have been based on proteins that transport paramagnetic species such as Mn^{2+} [11], gadolinium chelates [43], transferrin [44, 45] or ferritin [46] into cells or trap small molecule CEST reporters [47]. Alternatively, proteins have been engineered to display biotin on the cell surface, allowing binding and accumulation of an inorganic imaging agent linked to a biotin-binding protein such as streptavidin or transferrin [48, 49].

Since each protein potentially leads to accumulation of many contrast-generating molecules, reporters acting through amplified mechanisms can reach a high level of molecular sensitivity, and are therefore likely to find many uses. Their key limitations reflect the need to administer an exogenous agent prior to read-out, with concomitant pharmacokinetics and toxicity profiles, and the potential difficulty of interpreting quantitatively the resulting contrast with regard to biomolecule concentration. In addition, amplification introduces

substrate accumulation or activation kinetics into the temporal performance of these reporters, making it more difficult to engineer them as dynamic sensors.

4. Emerging Mechanisms of Biomolecular MRI: Diffusion, Hyperpolarization, and Hemodynamics

4.1. Diffusion based Reporters

One of the newest additions to biomolecular MRI is the use of water-permeable membrane channels as reporter genes for diffusion weighted imaging (DWI) (Fig. 1e). DWI is a widely-used technique in anatomical imaging, in which diffusion weighting is commonly achieved by applying a pair of pulsed magnetic field gradients, which dephase nuclear spins in proportion to how far they diffuse during a defined period [50–52]. Accordingly, water molecules that diffuse more freely have more severely dephased proton spins and appear darker in DWI. In biological tissues, the effective diffusivity of water depends on multiple parameters, including the local diffusivity in intracellular and extracellular compartments, the relative volume fraction occupied by cells, and the exchange rate of water across the plasma membrane [53–55].

In light of the importance of transmembrane diffusion, it was recently proposed that facilitating water exchange across the membrane by overexpressing water-permeable channels would result in enhanced contrast in DWI or more specialized sequences [56, 57]. The most natural class of molecules for achieving this goal is aquaporins, a highly conserved family of tetrameric integral membrane proteins that mediate the selective exchange of water molecules across the plasma membrane in a wide range of cell types [58–63]. In 2016, Mukherjee *et al.* demonstrated that mammalian cells engineered to overexpress the human gene aquaporin 1 (AQP1) using lentiviral vectors could be visualized by DWI *in vitro* and in tumor xenografts in mice (Fig. 2a, b). Strikingly, expression in cultured cells at concentrations as low as 500 nM (or 14 $\mu\text{g}/\text{mL}$ for the 28 kDa aquaporin protein) resulted in changes in the apparent diffusion coefficient (ADC) of 50% [56].

Making aquaporin work as a sensitive reporter gene required the use of a stimulated echo DWI sequence rather than standard spin echo DWI [53, 64]. This is because longer timescales are needed for water molecules to encounter membranes as a diffusion barrier (Fig. 2c). The key pulse sequence parameter driving this interaction is known as τ , which needs to be 100 ms or longer to produce pronounced aquaporin-dependent contrast, whereas in typical DWI, $\tau \sim 10$ ms. This dependence was examined in detail via Monte Carlo simulations and experiments (Fig. 2c). At $\tau = 398$ ms, an ADC change of more than 180% was measured in cells expressing AQP1 under a strong inducible promoter (Fig. 2d). Another parameter potentially affecting this contrast mechanism concerns the fraction of cells in a tissue that overexpresses aquaporin. For instance, one might imagine that a highly permeable cell surrounded by impermeable cells would have negligible influence on overall diffusivity. Interestingly, simulations and experiments both showed that while a non-linear relationship indeed exists between expressing fraction and overall contrast, sub-populations as small as 10% can be visualized. Based on their high sensitivity and functionality in mixed

populations, aquaporins should be useful for genetically labeling cell-based therapeutics to track them in the context of animal models and potentially in human patients.

Aquaporin overexpression is non-toxic, as shown in three cell lines and tumor xenografts engineered to overexpress aquaporins [56]. This is not surprising, since aquaporins such as AQP1 are highly selective for water, which they simply allow to diffuse back and forth across the cell membrane under the osmotically balanced conditions existing in all but a few body organs. Two further advantages of this class of reporter genes are that it requires no metals or exogenously administered contrast agents and can be autologous to the host species, reducing concerns about reporter immunogenicity. In addition, aquaporin produces contrast orthogonal to paramagnetic and CEST reporters, potentially allowing multiplexing. Furthermore, the wide variety of aquaporin genes present across all domains of life opens the door to engineering improved and potentially functional biomolecular reporters.

One limitation of aquaporin as a reporter gene is the variation in endogenous water diffusivity across tissue types, driven by factors such as cell size and density, as well as native expression of aquaporins. Tissues with inherently low water diffusivity are the most suitable for imaging with aquaporins, provided that the aquaporin reporter gene can be delivered and expressed in the tissue using established approaches for gene delivery such as viral vectors. For instance, tumors, with their dense cellularity and low background diffusion, are ideal tissues to express aquaporin reporters to image gene expression in preclinical animal models, while the brain, with its comparatively lower cellularity and inherently high aquaporin expression in glia, has a more diffusive background making the detection of aquaporin overexpression more challenging. These issues may be partially addressed with pulse sequence development; for example, acquiring DWI images at multiple values of b would help distinguish contrast based on cell permeability from contrast based on morphology. In addition, animal models involving genetic knockdown of endogenous aquaporins [62, 63] may be used to reduce native aquaporin expression to generate local contrast in high-expressing tissues.

In addition to aquaporin, a separate study recently reported that the urea transporter (UT-B) could also be used as a reporter gene based on its ability to increase the permeability of cell membranes [57]. In addition to urea, UT-B is able to transport water at rates similar to aquaporin. UT-B expression was visualized using a filter-exchange imaging (FEXI) sequence, in which a pulsed gradient is first used to dephase fast-diffusing extracellular water, then a variable time is given for exchange of water from this compartment with the slower-diffusing cytoplasmic water, after which a second diffusion-weighting is applied to measure the apparent diffusivity. Membrane permeability results in faster exchange between the compartments, allowing the ADC to return to equilibrium more quickly. Using this sequence, the apparent exchange rate between the two compartments increased by up to ~100% with UT-B expression *in vitro*, and it was possible to image gene expression *in vivo*. Notably, no significant changes in ADC were measured in cells expressing UT-B, which is likely due to the study's use of a spin echo DWI sequence with a short τ_{echo} .

4.2. Reporters for hyperpolarized MRI

Among the recent breakthroughs in molecular MRI is hyperpolarization - the preparation of nuclear spins in nonequilibrium states of high magnetization. This technology directly addresses the relatively low sensitivity of MRI, which is fundamentally due to the weakness of the interaction of nuclear spins with the applied magnetic field relative to Boltzmann energy. Hyperpolarization can be performed via several methods, including dynamic nuclear polarization (DNP) [65, 66], symmetry-breaking chemical reactions with parahydrogen [67–69], and gas phase collisional spin exchange with optically excited alkalis [70–72], resulting, in the most favorable cases, in polarization increases on the order of 10,000-fold compared to thermal equilibrium [73, 74]. Molecules hyperpolarized using these methods can then be introduced into *in vitro* specimens and *in vivo* organisms, where their nonequilibrium polarization has a lifetime governed by T_1 [75–78]. Importantly, because of the much higher net magnetization, imaging can be performed at much lower nucleus concentrations. Hyperpolarized organic compounds, such as ^{13}C -pyruvate and fumarate, are typically imaged in a single shot following injection into the body, revealing their transport and metabolism [79] (using chemical shift imaging), which can provide clinically valuable information about diseases such as cancer [76, 80] and renal disorders [77]. Similarly, hyperpolarized noble gases such as ^{129}Xe can be delivered into the body repeatedly via inhalation, producing gas-phase contrast in the lungs and solution-phase contrast in perfused tissues.

The increased average signal of hyperpolarized nuclei naturally motivates the development of contrast agents acting on molecules containing such nuclei (Fig. 1f). In particular, the biocompatibility and renewable (via inhalation) magnetization of ^{129}Xe , has made it an attractive target for contrast agent development. In 2006, a seminal study by Schröder *et al.* [81] showed that organic compounds designed to bind xenon and alter its chemical shift could produce MRI contrast at nanomolar concentrations using the hyperpolarized analog of CEST, named HyperCEST. In this technique, saturation is applied at the chemical shift of xenon in the chemical host, which is then transferred to aqueous xenon via chemical exchange. In addition to the strong, hyperpolarized starting signal, this technique benefits from the high specificity of the host-bound xenon's chemical shift and its large separation (~ 100 ppm) from the aqueous peak. Several groups have developed innovative reporters and sensors based on Xe-binding hosts [82–86].

Initially, the prospect of developing analogous biomolecular HyperCEST reporters was considered remote due to the weak and short-lived interaction of xenon with most proteins [87–91]. However, in 2014 a study by Shapiro *et al.* showed that an unusual class of gas-filled protein nanostructures called gas vesicles (GVs) could interact with hyperpolarized xenon so as to produce HyperCEST contrast at picomolar concentrations [92]. GV, which evolved in photosynthetic microbes as a means to regulate buoyancy, comprise hollow gas compartments with dimensions on the order of 250 nm, enclosed by a 2 nm-thick protein shell, which is permeable to gas but excludes liquid water [93, 94] (Fig. 3, a–b). The study showed that GV can interact with xenon to produce HyperCEST contrast with peak saturation approximately 175 ppm upfield from dissolved ^{129}Xe (Fig. 3, c–d). The large chemical shift separation enables the contrast to be extremely efficient, with a GV detection

limit in the picomolar range (Fig. 3e), orders of magnitude lower than comparable proton contrast agents. Furthermore, GVs formed by different species of bacteria and archaea, in which these nanostructures differ in size and shape, produce HyperCEST saturation at different chemical shifts, thereby enabling multiplexed imaging. GVs have been shown to produce contrast as antibody-functionalized markers of cancer cells and as reporters of gene expression in *E. coli*.

The development of GVs as biomolecular reporters for HyperCEST leads to several interesting avenues for further investigation. For example, it will be interesting to study how the chemical shift observed for different types of particles relates to their genetically encoded properties, including size, shape, clustering state and the amino acid composition of their shell. Also important are the quantitative parameters defining the efficiency of HyperCEST contrast, including the binding capacity of GVs for xenon and the rate of exchange with surrounding media, which can be studied using the quantitative HyperCEST methodology developed by Kunth *et al.* [95]. This will enable the development of optimal radiofrequency saturation parameters for the specific exchange rate of GVs, and open the door to further engineering at the molecular level.

In addition to GVs, other biological structures may be able to serve as HyperCEST agents. For example, bacterial spores, a dormant cellular state comprising a multi-layered structure of ~ 1.5 μm size, were recently demonstrated for HyperCEST at a chemical shift 4.5 ppm downfield from aqueous xenon [84]. In addition, using strong saturation to compensate for fast exchange, it is possible to perform HyperCEST based on chemical exchange between free xenon in solution and xenon bound to the small protein, beta-lactamase [85].

Besides ^{129}Xe , other hyperpolarized molecules that have been paired with biomolecular reporters including ^{13}C labeled molecules such as N-acetyl-L-methionine (paired with aminoacylase) [96], 3,5-difluorobenzyl-L-glutamic acid (paired with carboxypeptidase G2) [97], pyruvate (paired with pyruvate decarboxylase) [98], urea (DWI with urea transporter UT-B) [99], and ^{19}F labeled substrates that interact with bovine trypsin [100].

Ultimately, the effectiveness of hyperpolarized reporters *in vivo* depends on the ability of their cognate nuclei to reach target tissues while retaining significant polarization. In the case of ^{129}Xe , its solubility (Ostwald coefficient 0.14) and T_1 half-life (~ 10 s) suggest that the concentration of hyperpolarized xenon in a vascularized tissue such as the brain in mice will be on the order of 100 μM (assuming breathing of a 50% mixture of half-polarized, isotopically enriched ^{129}Xe). At this concentration, and correcting for the longer effective T_1 time of polarization replenishment by inhalation, SNR is expected to be ~ 1% that of proton MRI, reducing overall spatial resolution. However, the molecular sensitivity will be sub-nanomolar. Assuming the need to saturate 66% of the signal over a timescale of T_1 , an exchange rate of 10 kHz and an occupancy of 1,000 xenon atoms per GV, this results in a detection limit of ~ 10 pM particles or 4 $\mu\text{g}/\text{mL}$ protein. Translating HyperCEST to *in vivo* applications is a major focus of ongoing research.

4.3. Reporters modulating hemodynamics

Another recently introduced mechanism for biomolecular MRI involves peptides that act on smooth muscle cells to increase blood flow locally, resulting in blood oxygenation level dependent (BOLD) contrast [101] (Fig. 1g). Blood perfusion is naturally modulated in tissues based on metabolic demand via signaling molecules such as nitric oxide, and peptides such as the calcitonin gene related peptide (CGRP) [102, 103]. It was shown recently that local injection or cellular secretion of CGRP could elicit changes in BOLD contrast. Impressively, ~ 10 nM concentrations of this molecule were sufficient to produce this effect. CGRP can be considered a new kind of amplified reporter. Rather than acting directly on nuclear spins, it elicits a local change in the concentration of a paramagnetic contrast agent, in this case deoxyhemoglobin. However, unlike most other amplified reporters, no external administration of contrast agents is required, and kinetics can be rapid, since the blood flow can increase and decrease on a second timescale in response to appropriate signals. Furthermore, CGRP can be engineered as a molecular sensor, for example by incorporating autoinhibitory domains that become cleaved by proteases [101].

One potential limitation of hemodynamics-based reporters is the presence of active, fluctuating background signal in tissues such as the brain. However, this can be distinguished from reporter-induced signal by its kinetics or by inhibition of the background signaling. The potential effects of such inhibition, or of repeated or prolonged release of CGRP on physiology, also merit further study as this technology moves to broader adoption.

5. Outlook

The development of new classes of biomolecules that produce MRI contrast, such as water channels, vasomodulatory peptides, and gas vesicles is a significant step forward in expanding the capabilities of biomolecular MRI beyond the realm of conventional contrast mechanisms. Moving ahead, additional breakthroughs are possible through the discovery or engineering of biomolecules that leverage other emerging contrast mechanisms, which have thus far been limited to synthetic implementations. Notable examples include paramagnetic CEST (paraCEST) agents, parahydrogen-induced hyperpolarized molecules, and magnetic resonance energy transfer (MRET) -based sensors.

ParaCEST imaging achieves enhanced CEST sensitivity through the use of paramagnetic ions to induce large chemical shifts (50–100 ppm) in the resonance frequency of exchangeable protons, thereby enabling highly selective saturation and faster proton exchange compared with conventional CEST [36, 104]. Bioavailable metals such as iron [105], cobalt [106], and nickel [107] are well suited for paraCEST, which suggests that naturally occurring Ni, Co, and Fe-based metalloproteins could be developed as paraCEST reporter genes. Another approach to boost the sensitivity of MRI is parahydrogen induced polarization (PHIP) [68, 69]. In this technique, hyperpolarization is spontaneously transferred from the singlet parahydrogen spin state of H₂ gas to a suitable substrate via chemical hydrogenation or reversible exchange at a catalytic site to achieve ~ 800 to 5000-fold gain in NMR signal for protons or heteronuclei (such as ¹³C, ¹⁵N, ¹⁹F) in the substrate molecule [67, 69]. Hyperpolarization transfer is typically achieved using solvent-phase catalysis with organometallic complexes, which has constrained the *in vivo* applicability of

parahydrogen-based molecular imaging owing to toxicity concerns [108]. The development of biomolecular catalysts for aqueous phase hydrogenation or exchange-based transfer to polarize bioactive molecules in water would greatly simplify the translation of this highly sensitive MRI approach to living animals.

In addition to reporters, there is a great need for molecular sensors to dynamically interrogate cellular function. From this standpoint, new reporter proteins such as aquaporins and gas vesicles could serve as the basis for developing biomolecular sensors by leveraging tools and principles of protein engineering and synthetic biology [109], as has been done with T_1 , T_2 and CEST-based sensors [9, 18, 32]. In addition, a new mechanism for modulating MRI contrast, called MRET [110], may provide another avenue towards dynamic MRI sensors analogous to optical reporters based on Förster resonance energy transfer (FRET). In MRET, T_1 relaxation is tuned by controlling the nanoscale separation between a paramagnetic T_1 enhancer (such as a synthetic Gd-chelate) and a superparamagnetic quencher nanoparticle (such as iron oxide). Reducing the distance between the paramagnetic enhancer and the quencher narrows the spectral density of electron spin fluctuations, leading to inefficient paramagnetic relaxation and longer T_1 times [110]. The implementation of this concept in biomolecular sensors depends on first achieving biomineralization of strongly magnetic materials in cells. Biomolecular mineralization of super-paramagnetic materials would also enable their application for magnetic particle imaging (MPI) imaging, which has the potential to achieve background-free imaging with high sensitivity using direct detection of particle magnetization rather than water magnetic resonance [111, 112]. In summary, we envision that the evolution of future generations of sensitive biomolecular MRI reporters and cellular sensors will play a crucial role in expanding the scope of truly functional imaging in the context of living animals.

Acknowledgments

Work in the Shapiro laboratory related to this article is supported by the Heritage Medical Research Institute, the Burroughs Wellcome Career Award at the Scientific Interface, the Pew Scholarship in the Biomedical Sciences, the Packard Fellowship for Science and Engineering, the Dana Foundation, the Human Frontier Science Program, the W.M. Keck Foundation and the National Institutes of Health (U54CA199090A). AM was supported by the James G. Boswell Postdoctoral Fellowship. PR was supported by a NSF Graduate Research Fellowship and the NIH Biotechnology Leaders Program.

Appendix

Calculations assume a background signal-to-noise ratio (SNR) of 400, adapted from [1], and yield the reporter concentration needed to achieve a contrast-to-noise ratio (CNR) of 5 by producing a 1.25% change in signal [2] (see Tables 2 and 3 for lists of the various symbols and assumed parameters).

Concentration of T_1 contrast agent needed to achieve a CNR of 5

The evolution of longitudinal magnetization in a T_1 -weighted experiment can be described using the following equation [117]:

$$\frac{S}{S_0} = 1 - \exp(-R_1 T_R) \quad (\text{A1})$$

To achieve a CNR of 5, the T_1 agent must enhance longitudinal magnetization by a factor of 1.25% relative to the background signal:

$$\frac{\Delta S}{S_{\text{bkg}}} = \frac{S_{\text{CA}} - S_{\text{bkg}}}{S_{\text{bkg}}} = 0.0125 \quad (\text{A2})$$

$$\Rightarrow \frac{\exp(-R_{1,\text{bkg}} T_R) - \exp(-R_{1,\text{CA}} T_R)}{1 - \exp(-R_{1,\text{bkg}} T_R)} = 0.0125 \quad (\text{A3})$$

The relaxation rate in the presence of a contrast agent can be expressed by the following equation:

$$R_{1,\text{CA}} = R_{1,\text{bkg}} + x_{\text{CA}} r_{\text{CA}} \quad (\text{A4})$$

Substituting the value of $R_{1,\text{CA}}$ from Eq. (A4) in Eq. (A3), we arrive at the following expression for contrast agent concentration:

$$x_{\text{CA}} + \frac{R_{1,\text{bkg}}}{r_{\text{CA}}} + \frac{\ln(1.0125 \exp(-R_{1,\text{bkg}} T_R) - 0.0125)}{T_R r_{\text{CA}}} = 0 \quad (\text{A5})$$

To calculate the optimal T_R , we use Eq. (A6), which evaluates the T_R that maximizes signal relative to background:

$$T_{R,\text{opt}} = \frac{\ln\left(\frac{R_{1,\text{CA}}}{R_{1,\text{bkg}}}\right)}{R_{1,\text{CA}} - R_{1,\text{bkg}}} = \frac{\ln\left(1 + \frac{x_{\text{CA}} r_{\text{CA}}}{R_{1,\text{bkg}}}\right)}{x_{\text{CA}} r_{\text{CA}}} \quad (\text{A6})$$

Eq. (A5) and (A6) can be solved numerically to evaluate x_{CA} which is the minimum concentration of the T_1 agent needed to produce a 1.25% signal enhancement using an optimized T_R time.

Concentration of T_2 contrast agent needed to achieve a CNR of 5

A similar approach can be used to calculate the minimum concentration of T_2 agent required to produce a 1.25% decrease in signal relative to background. In this case, dephasing of transverse magnetization from spin-spin interactions is described by the following equation [117]:

$$\frac{S}{S_0} = \exp(-R_2 T_E) \quad (\text{A7})$$

To achieve a CNR of 5, the T_2 agent must reduce the MRI signal by a factor of 1.25% relative to the background:

$$\frac{\Delta S}{S_{\text{bkgr}}} = \frac{S_{CA} - S_{\text{bkgr}}}{S_{\text{bkgr}}} = -0.0125 \Rightarrow \frac{\exp(-R_{2,CA} T_E) - \exp(-R_{2,\text{bkgr}} T_E)}{\exp(-R_{2,\text{bkgr}} T_E)} = -0.0125 \quad (\text{A8})$$

The relaxation rate produced by a contrast agent can be approximated by the following equation:

$$R_{2,CA} = R_{2,\text{bkgr}} + x_{CA} r_{CA} \quad (\text{A9})$$

Substituting the value of $R_{2,CA}$ from Eq. (9) in Eq. (8), we arrive at the following expression for contrast agent concentration:

$$x_{CA} + \frac{\ln(0.9875)}{T_E r_{CA}} = 0 \quad (\text{A10})$$

To calculate the optimal T_E , we use Eq. (11), which evaluates the T_E that maximizes signal relative to background:

$$T_{E,\text{opt}} = \frac{\ln\left(\frac{R_{2,CA}}{R_{2,\text{bkgr}}}\right)}{R_{2,CA} - R_{2,\text{bkgr}}} = \frac{\ln\left(1 + \frac{x_{CA} r_{CA}}{R_{2,\text{bkgr}}}\right)}{x_{CA} r_{CA}} \quad (\text{A11})$$

Eq. (10) and (11) can be solved analytically to evaluate x_{CA} which is the minimum concentration of the T_2 agent needed to produce a 1.25% signal change using an optimal T_E time.

Concentration of CEST agent needed to achieve a CNR of 5

Steady state proton transfer ratio for a CEST agent can be described using the following equation [35]:

$$\text{PTR} = \left(\frac{x_{CA}}{x_{H_2O}}\right) n_{CA} \alpha k_{CA \rightarrow w} T_1 \left(1 - \exp\left(-\frac{t_{\text{sat}}}{T_1}\right)\right) = 0.0125 \quad (\text{A12})$$

The minimum concentration of a CEST reporter required to achieve a signal change of 1.25% can be calculated directly from the above equation.

References

1. DiFrancesco M, Rasmussen J, Yuan W, Pratt R, Dunn S, Dardzinski B, Holland S. Comparison of SNR and CNR for in vivo mouse brain imaging at 3 and 7T using well matched scanner configurations. *Medical physics*. 2008; 35:3972–3978. [PubMed: 18841848]
2. Mills PH, Ahrens ET. Theoretical MRI contrast model for exogenous T2 agents. *Magnetic resonance in medicine*. 2007; 57:442–447. [PubMed: 17260382]
3. Gilad AA, Winnard PT, van Zijl P, Bulte JW. Developing MR reporter genes: promises and pitfalls. *NMR in biomedicine*. 2007; 20:275–290. [PubMed: 17451181]
4. Lee S-W, Lee S-H, Biswal S. Magnetic resonance reporter gene imaging. *Theranostics*. 2012; 2:403–412. [PubMed: 22539936]
5. Jasanoff A. MRI contrast agents for functional molecular imaging of brain activity. *Current opinion in neurobiology*. 2007; 17:593–600. [PubMed: 18093824]
6. Gilad AA, Ziv K, McMahon MT, Van Zijl PC, Neeman M, Bulte JW. MRI reporter genes. *Journal of Nuclear Medicine*. 2008; 49:1905–1908. [PubMed: 18997049]
7. Vandsburger MH, Radoul M, Cohen B, Neeman M. MRI reporter genes: applications for imaging of cell survival, proliferation, migration and differentiation. *NMR in Biomedicine*. 2013; 26:872–884. [PubMed: 23225197]
8. Matsumoto Y, Jasanoff A. Metalloprotein-based MRI probes. *FEBS letters*. 2013; 587:1021–1029. [PubMed: 23376346]
9. Shapiro MG, Westmeyer GG, Romero PA, Szablowski JO, Küster B, Shah A, Otey CR, Langer R, Arnold FH, Jasanoff A. Directed evolution of a magnetic resonance imaging contrast agent for noninvasive imaging of dopamine. *Nature biotechnology*. 2010; 28:264–270.
10. Bartelle BB, Mana MD, Suero-Abreu GA, Rodriguez JJ, Turnbull DH. Engineering an effective Mn-binding MRI reporter protein by subcellular targeting. *Magnetic resonance in medicine*. 2015; 74:1750–1757. [PubMed: 25522343]
11. Bartelle BB, Szulc KU, Suero-Abreu GA, Rodriguez JJ, Turnbull DH. Divalent metal transporter, DMT1: A novel MRI reporter protein. *Magnetic resonance in medicine*. 2013; 70:842–850. [PubMed: 23065715]
12. Hai A, Cai LX, Lee T, Lelyveld VS, Jasanoff A. Molecular fMRI of Serotonin Transport. *Neuron*. 2016; 92:754–765. [PubMed: 27773583]
13. Lee T, Cai LX, Lelyveld VS, Hai A, Jasanoff A. Molecular-level functional magnetic resonance imaging of dopaminergic signaling. *Science*. 2014; 344:533–535. [PubMed: 24786083]
14. Lelyveld VS, Brustad E, Arnold FH, Jasanoff A. Metal-substituted protein MRI contrast agents engineered for enhanced relaxivity and ligand sensitivity. *Journal of the American Chemical Society*. 2011; 133:649–651. [PubMed: 21171606]
15. Xue S, Yang H, Qiao J, Pu F, Jiang J, Hubbard K, Hekmatyar K, Langley J, Salarian M, Long RC. Protein MRI contrast agent with unprecedented metal selectivity and sensitivity for liver cancer imaging. *Proceedings of the National Academy of Sciences*. 2015; 112:6607–6612.
16. Caravan P, Farrar CT, Frullano L, Uppal R. Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents. *Contrast media & molecular imaging*. 2009; 4:89–100. [PubMed: 19177472]
17. Gossuin Y, Gillis P, Hocq A, Vuong QL, Roch A. Magnetic resonance relaxation properties of superparamagnetic particles. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*. 2009; 1:299–310. [PubMed: 20049798]
18. Shapiro MG, Szablowski JO, Langer R, Jasanoff A. Protein nanoparticles engineered to sense kinase activity in MRI. *Journal of the American Chemical Society*. 2009; 131:2484. [PubMed: 19199639]
19. Gossuin Y, Muller RN, Gillis P, Bartel L. Relaxivities of human liver and spleen ferritin. *Magnetic resonance imaging*. 2005; 23:1001–1004. [PubMed: 16376184]
20. Cunningham CH, Arai T, Yang PC, McConnell MV, Pauly JM, Conolly SM. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. *Magnetic Resonance in Medicine*. 2005; 53:999–1005. [PubMed: 15844142]

21. Terreno E, Castelli DD, Viale A, Aime S. Challenges for molecular magnetic resonance imaging. *Chemical reviews*. 2010; 110:3019–3042. [PubMed: 20415475]
22. Davis HC, Ramesh P, Bhatnagar A, Lee-Gosselin A, Barry JF, Glenn DR, Walsworth RL, Shapiro MG. Mapping the Microscale Origins of MRI Contrast with Subcellular NV Diamond Magnetometry. *arXiv preprint arXiv:1610.01924*. 2016
23. Bulte JW, Douglas T, Mann S, Frankel RB, Moskowitz BM, Brooks RA, Baumgarner CD, Vymazal J, Strub MP, Frank JA. Magnetoferritin: characterization of a novel superparamagnetic MR contrast agent. *Journal of Magnetic Resonance Imaging*. 1994; 4:497–505. [PubMed: 7802866]
24. Kolinko I, Lohße A, Borg S, Raschdorf O, Jogler C, Tu Q, Pósfai M, Tompa É, Pitzko JM, Brachmann A. Biosynthesis of magnetic nanostructures in a foreign organism by transfer of bacterial magnetosome gene clusters. *Nature nanotechnology*. 2014; 9:193–197.
25. Matsumoto Y, Chen R, Anikeeva P, Jasanoff A. Engineering intracellular biomineralization and biosensing by a magnetic protein. *Nature communications*. 2015; 6:8721.
26. Liu X, Lopez PA, Giessen TW, Giles M, Way JC, Silver PA. Engineering Genetically-Encoded Mineralization and Magnetism via Directed Evolution. *Scientific Reports*. 2016; 6:38019. [PubMed: 27897245]
27. Radoul M, Lewin L, Cohen B, Oren R, Popov S, Davidov G, Vandsburger MH, Harmelin A, Bitton R, Greneche J-M. Genetic manipulation of iron biomineralization enhances MR relaxivity in a ferritin-M6A chimeric complex. *Scientific reports*. 2016; 6:26550. [PubMed: 27211820]
28. Sun PZ, Schoening ZB, Jasanoff A. In vivo oxygen detection using exogenous hemoglobin as a contrast agent in magnetic resonance microscopy. *Magnetic resonance in medicine*. 2003; 49:609–614. [PubMed: 12652529]
29. Weissleder R, Simonova M, Bogdanova A, Bredow S, Enochs WS, Bogdanov A Jr. MR imaging and scintigraphy of gene expression through melanin induction. *Radiology*. 1997; 204:425–429. [PubMed: 9240530]
30. Zhang X-Y, Robledo BN, Harris SS, Hu XP. A bacterial gene, *mms6*, as a new reporter gene for magnetic resonance imaging of mammalian cells. *Mol Imaging*. 2014; 13:1–12.
31. Bar-Shir A, Liu G, Chan KW, Oskolkov N, Song X, Yadav NN, Walczak P, McMahon MT, van Zijl PC, Bulte JW. Human protamine-I as an MRI reporter gene based on chemical exchange. *ACS chemical biology*. 2014; 9:134–138. [PubMed: 24138139]
32. Airan RD, Bar-Shir A, Liu G, Pelled G, McMahon MT, van Zijl P, Bulte JW, Gilad AA. MRI biosensor for protein kinase A encoded by a single synthetic gene. *Magnetic resonance in medicine*. 2012; 68:1919–1923. [PubMed: 23023588]
33. Gilad AA, McMahon MT, Walczak P, Winnard PT, Raman V, van Laarhoven HW, Skoglund CM, Bulte JW, van Zijl PC. Artificial reporter gene providing MRI contrast based on proton exchange. *Nature biotechnology*. 2007; 25:217–219.
34. McMahon MT, Gilad AA, DeLiso MA, Cromer Berman SM, Bulte JW, van Zijl P. New “multicolor” polypeptide diamagnetic chemical exchange saturation transfer DIACEST contrast agents for MRI. *Magnetic Resonance in Medicine*. 2008; 60:803–812. [PubMed: 18816830]
35. van Zijl P, Yadav NN. Chemical exchange saturation transfer (CEST): what is in a name and what isn't? *Magnetic resonance in medicine*. 2011; 65:927–948. [PubMed: 21337419]
36. Sherry AD, Woods M. Chemical exchange saturation transfer contrast agents for magnetic resonance imaging. *Annu. Rev. Biomed. Eng.* 2008; 10:391–411. [PubMed: 18647117]
37. Liu G, Song X, Chan KW, McMahon MT. Nuts and bolts of chemical exchange saturation transfer MRI. *NMR in Biomedicine*. 2013; 26:810–828. [PubMed: 23303716]
38. Farrar CT, Buhman JS, Liu G, Kleijn A, Lamfers ML, McMahon MT, Gilad AA, Fulci G. Establishing the lysine-rich protein CEST reporter gene as a CEST MR imaging detector for oncolytic virotherapy. *Radiology*. 2015; 275:746–754. [PubMed: 25686366]
39. Minn I, Bar-Shir A, Yarlagadda K, Bulte JW, Fisher PB, Wang H, Gilad AA, Pomper MG. Tumor-specific expression and detection of a CEST reporter gene. *Magnetic resonance in medicine*. 2015; 74:544–549. [PubMed: 25919119]

40. Song X, Gilad AA, Joel S, Liu G, Bar-Shir A, Liang Y, Gorelik M, Pekar JJ, van Zijl P, Bulte JW. CEST phase mapping using a length and offset varied saturation (LOVARS) scheme. *Magnetic resonance in medicine*. 2012; 68:1074–1086. [PubMed: 22246684]
41. Koretsky AP, Brosnan MJ, Chen L, Chen J, Van Dyke T. NMR detection of creatine kinase expressed in liver of transgenic mice: determination of free ADP levels. *Proceedings of the National Academy of Sciences*. 1990; 87:3112–3116.
42. Louie AY, Hüber MM, Ahrens ET, Rothbächer U, Moats R, Jacobs RE, Fraser SE, Meade TJ. In vivo visualization of gene expression using magnetic resonance imaging. *Nature biotechnology*. 2000; 18:321–325.
43. Patrick PS, Hammersley J, Loizou L, Kettunen MI, Rodrigues TB, Hu D-E, Tee S-S, Hesketh R, Lyons SK, Soloviev D. Dual-modality gene reporter for in vivo imaging. *Proceedings of the National Academy of Sciences*. 2014; 111:415–420.
44. Deans AE, Wadghiri YZ, Bernas LM, Yu X, Rutt BK, Turnbull DH. Cellular MRI contrast via coexpression of transferrin receptor and ferritin. *Magnetic resonance in medicine*. 2006; 56:51–59. [PubMed: 16724301]
45. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP. In vivo magnetic resonance imaging of transgene expression. *Nature medicine*. 2000; 6:351–354.
46. Patrick PS, Rodrigues TB, Kettunen MI, Lyons SK, Neves AA, Brindle KM. Development of Timd2 as a reporter gene for MRI. *Magnetic resonance in medicine*. 2015; 75:1697–1707. [PubMed: 25981669]
47. Bar-Shir A, Liu G, Liang Y, Yadav NN, McMahon MT, Walczak P, Nimmagadda S, Pomper MG, Tallman KA, Greenberg MM. Transforming thymidine into a magnetic resonance imaging probe for monitoring gene expression. *Journal of the American Chemical Society*. 2013; 135:1617–1624. [PubMed: 23289583]
48. Tannous BA, Grimm J, Perry KF, Chen JW, Weissleder R, Breakefield XO. Metabolic biotinylation of cell surface receptors for in vivo imaging. *Nature methods*. 2006; 3:391–396. [PubMed: 16628210]
49. Bartelle BB, Berríos-Otero CA, Rodríguez JJ, Friedland AE, Aristizábal O, Turnbull DH. Novel Genetic Approach for In Vivo Vascular Imaging in Mice. *Circulation research*. 2012; 110:938–947. [PubMed: 22374133]
50. Le Bihan D. Looking into the functional architecture of the brain with diffusion MRI. *Nature Reviews Neuroscience*. 2003; 4:469–480. [PubMed: 12778119]
51. Neil JJ. Diffusion imaging concepts for clinicians. *Journal of Magnetic Resonance Imaging*. 2008; 27:1–7. [PubMed: 18050325]
52. Norris DG. The effects of microscopic tissue parameters on the diffusion weighted magnetic resonance imaging experiment. *NMR in Biomedicine*. 2001; 14:77–93. [PubMed: 11320535]
53. Li H, Jiang X, Xie J, McIntyre JO, Gore JC, Xu J. Time-dependent influence of cell membrane permeability on MR diffusion measurements. *Magnetic resonance in medicine*. 2015; 75:1927–1934. [PubMed: 26096552]
54. Badaut J, Fukuda AM, Jullienne A, Petry KG. Aquaporin and brain diseases. *Biochimica et Biophysica Acta (BBA)-General Subjects*. 2014; 1840:1554–1565. [PubMed: 24513456]
55. Sehy JV, Banks AA, Ackerman JJ, Neil JJ. Importance of intracellular water apparent diffusion to the measurement of membrane permeability. *Biophysical journal*. 2002; 83:2856–2863. [PubMed: 12414717]
56. Mukherjee A, Wu D, Davis HC, Shapiro MG. Non-invasive imaging using reporter genes altering cellular water permeability. *Nature Communications*. 2016; 7:13891.
57. Schilling F, Ros S, Hu D-E, D'Santos P, McGuire S, Mair R, Wright AJ, Mannion E, Franklin RJ, Neves AA. MRI measurements of reporter-mediated increases in transmembrane water exchange enable detection of a gene reporter. *Nature Biotechnology*. 2017; 35:75–80.
58. Yang B, Verkman A. Water and glycerol permeabilities of aquaporins 1–5 and MIP determined quantitatively by expression of epitope-tagged constructs in *Xenopus* oocytes. *Journal of Biological Chemistry*. 1997; 272:16140–16146. [PubMed: 9195910]

59. Sukstanskii A, Yablonskiy D, Ackerman J. Effects of permeable boundaries on the diffusion-attenuated MR signal: insights from a one-dimensional model. *Journal of Magnetic Resonance*. 2004; 170:56–66. [PubMed: 15324758]
60. Ma T, Frigeri A, Tsai S-T, Verbavatz J, Verkman A. Localization and functional analysis of CHIP28k water channels in stably transfected Chinese hamster ovary cells. *Journal of Biological Chemistry*. 1993; 268:22756–22764. [PubMed: 8226786]
61. Agre P, Bonhivers M, Borgnia MJ. The aquaporins, blueprints for cellular plumbing systems. *Journal of Biological Chemistry*. 1998; 273:14659–14662. [PubMed: 9614059]
62. Badaut J, Ashwal S, Adami A, Tone B, Recker R, Spagnoli D, Ternon B, Obenaus A. Brain water mobility decreases after astrocytic aquaporin-4 inhibition using RNA interference. *Journal of Cerebral Blood Flow & Metabolism*. 2011; 31:819–831. [PubMed: 20877385]
63. Fukuda AM, Adami A, Pop V, Bellone JA, Coats JS, Hartman RE, Ashwal S, Obenaus A, Badaut J. Posttraumatic reduction of edema with aquaporin-4 RNA interference improves acute and chronic functional recovery. *Journal of Cerebral Blood Flow & Metabolism*. 2013; 33:1621–1632. [PubMed: 23899928]
64. Pilatus U, Shim H, Artemov D, Davis D, Van Zijl P, Glickson JD. Intracellular volume and apparent diffusion constants of perfused cancer cell cultures, as measured by NMR. *Magnetic resonance in medicine*. 1997; 37:825–832. [PubMed: 9178232]
65. Griffin R, Prisner T. High field dynamic nuclear polarization—the renaissance. *Physical Chemistry Chemical Physics*. 2010; 12:5737–5740. [PubMed: 20485782]
66. Wolber J, Ellner F, Fridlund B, Gram A, Johannesson H, Hansson G, Hansson L, Lerche MH, Månsson S, Servin R. Generating highly polarized nuclear spins in solution using dynamic nuclear polarization, Nuclear Instruments and Methods in Physics Research Section A: Accelerators, Spectrometers, Detectors and Associated Equipment. 2004; 526:173–181.
67. Adams RW, Aguilar JA, Atkinson KD, Cowley MJ, Elliott PI, Duckett SB, Green GG, Khazal IG, López-Serrano J, Williamson DC. Reversible interactions with para-hydrogen enhance NMR sensitivity by polarization transfer. *Science*. 2009; 323:1708–1711. [PubMed: 19325111]
68. Natterer J, Bargon J. Parahydrogen induced polarization. *Progress in Nuclear Magnetic Resonance Spectroscopy*. 1997; 31:293–315.
69. Bowers CR, Weitekamp DP. Transformation of symmetrization order to nuclear-spin magnetization by chemical reaction and nuclear magnetic resonance. *Physical Review Letters*. 1986; 57:2645–2648. [PubMed: 10033824]
70. Navon G, Song Y, Room T, Appelt S. Enhancement of solution NMR and MRI with laser-polarized xenon. *Science*. 1996; 271:1848–1851.
71. Kauczor H-U, Surkau R, Roberts T. MRI using hyperpolarized noble gases. *European radiology*. 1998; 8:820–827. [PubMed: 9601972]
72. Walker TG, Happer W. Spin-exchange optical pumping of noble-gas nuclei. *Reviews of Modern Physics*. 1997; 69:629–642.
73. Ardenkjær-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of > 10,000 times in liquid-state NMR. *Proceedings of the National Academy of Sciences*. 2003; 100:10158–10163.
74. Ross B, Bhattacharya P, Wagner S, Tran T, Sailasuta N. Hyperpolarized MR imaging: neurologic applications of hyperpolarized metabolism. *American Journal of Neuroradiology*. 2010; 31:24–33. [PubMed: 19875468]
75. McCarney ER, Armstrong BD, Lingwood MD, Han S. Hyperpolarized water as an authentic magnetic resonance imaging contrast agent. *Proceedings of the National Academy of Sciences*. 2007; 104:1754–1759.
76. Brindle KM, Bohndiek SE, Gallagher FA, Kettunen MI. Tumor imaging using hyperpolarized ¹³C magnetic resonance spectroscopy. *Magnetic resonance in medicine*. 2011; 66:505–519. [PubMed: 21661043]
77. Clatworthy MR, Kettunen MI, Hu D-E, Mathews RJ, Witney TH, Kennedy BW, Bohndiek SE, Gallagher FA, Jarvis LB, Smith KG. Magnetic resonance imaging with hyperpolarized [1, 4-¹³C₂] fumarate allows detection of early renal acute tubular necrosis. *Proceedings of the National Academy of Sciences*. 2012; 109:13374–13379.

78. Henry P-G, Adriany G, Deelchand D, Gruetter R, Marjanska M, Öz G, Seaquist ER, Shestov A, K U urbil. In vivo ^{13}C NMR spectroscopy and metabolic modeling in the brain: a practical perspective. *Magnetic resonance imaging*. 2006; 24:527–539. [PubMed: 16677959]
79. Brindle KM. Imaging metabolism with hyperpolarized ^{13}C -labeled cell substrates. *Journal of the American Chemical Society*. 2015; 137:6418–6427. [PubMed: 25950268]
80. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I. Metabolic imaging of patients with prostate cancer using hyperpolarized [1- ^{13}C] pyruvate. *Science translational medicine*. 2013; 5:198.
81. Schröder L, Lowery TJ, Hilty C, Wemmer DE, Pines A. Molecular imaging using a targeted magnetic resonance hyperpolarized biosensor. *Science*. 2006; 314:446–449. [PubMed: 17053143]
82. Meldrum T, Seim KL, Bajaj VS, Palaniappan KK, Wu W, Francis MB, Wemmer DE, Pines A. A xenon-based molecular sensor assembled on an MS2 viral capsid scaffold. *Journal of the American Chemical Society*. 2010; 132:5936–5937. [PubMed: 20392049]
83. Stevens TK, Palaniappan KK, Ramirez RM, Francis MB, Wemmer DE, Pines A. HyperCEST detection of a ^{129}Xe -based contrast agent composed of cryptophane-A molecular cages on a bacteriophage scaffold. *Magnetic resonance in medicine*. 2013; 69:1245–1252. [PubMed: 22791581]
84. Bai Y, Wang Y, Goulian M, Driks A, Dmochowski IJ. Bacterial spore detection and analysis using hyperpolarized ^{129}Xe chemical exchange saturation transfer (Hyper-CEST) NMR. *Chemical Science*. 2014; 5:3197–3203. [PubMed: 25089181]
85. Wang Y, Roose BW, Palovcak EJ, Carnevale V, Dmochowski IJ. A Genetically Encoded β -Lactamase Reporter for Ultrasensitive ^{129}Xe NMR in Mammalian Cells. *Angewandte Chemie International Edition*. 2016; 55:8984–8987. [PubMed: 27305488]
86. Witte C, Martos V, Rose HM, Reinke S, Klippel S, Schröder L, Hackenberger CP. Live-cell MRI with Xenon Hyper-CEST Biosensors Targeted to Metabolically Labeled Cell-Surface Glycans. *Angewandte Chemie International Edition*. 2015; 54:2806–2810. [PubMed: 25676513]
87. Prange T, Schiltz M, Pernot L, Colloc'h N, Longhi S, Bourguet W, Fourme R. Exploring hydrophobic sites in proteins with xenon or krypton, *Proteins: Structure, Function, and Bioinformatics*. 1998; 30:61–73. [PubMed: 9443341]
88. Locci E, Dehouck Y, Casu M, Saba G, Lai A, Luhmer M, Reisse J, Bartik K. Probing proteins in solution by ^{129}Xe NMR spectroscopy. *Journal of magnetic resonance*. 2001; 150:167–174. [PubMed: 11384176]
89. Rubin SM, Lee S-Y, Ruiz EJ, Pines A, Wemmer DE. Detection and characterization of xenon-binding sites in proteins by ^{129}Xe NMR spectroscopy. *Journal of molecular biology*. 2002; 322:425–440. [PubMed: 12217701]
90. Bowers C, Storhaug V, Webster CE, Bharatam J, Cottone A III, Gianna R, Betsey K, Gaffney B. Exploring surfaces and cavities in lipoxxygenase and other proteins by hyperpolarized xenon- ^{129}Xe NMR. *Journal of the American Chemical Society*. 1999; 121:9370–9377. [PubMed: 16429610]
91. Tilton R Jr, Kuntz I Jr. Nuclear magnetic resonance studies of xenon- ^{129}Xe with myoglobin and hemoglobin. *Biochemistry*. 1982; 21:6850–6857. [PubMed: 7159568]
92. Shapiro MG, Ramirez RM, Sperling LJ, Sun G, Sun J, Pines A, Schaffer DV, Bajaj VS. Genetically encoded reporters for hyperpolarized xenon magnetic resonance imaging. *Nature chemistry*. 2014; 6:629–634.
93. Walsby A. Gas vesicles. *Microbiological reviews*. 1994; 58:94–144. [PubMed: 8177173]
94. Pfeifer F. Distribution, formation and regulation of gas vesicles. *Nature Reviews Microbiology*. 2012; 10:705–715. [PubMed: 22941504]
95. Kunth M, Witte C, Schröder L. Quantitative chemical exchange saturation transfer with hyperpolarized nuclei (qHyper-CEST): Sensing xenon-host exchange dynamics and binding affinities by NMR. *The Journal of chemical physics*. 2014; 141:194202. [PubMed: 25416884]
96. Chen AP, Hurd RE, Gu Yp, Wilson DM, Cunningham CH. ^{13}C MR reporter probe system using dynamic nuclear polarization. *NMR in biomedicine*. 2011; 24:514–520. [PubMed: 21674653]
97. Jamin Y, Gabellieri C, Smyth L, Reynolds S, Robinson SP, Springer CJ, Leach MO, Payne GS, Eykyn TR. Hyperpolarized ^{13}C magnetic resonance detection of carboxypeptidase G2 activity. *Magnetic resonance in medicine*. 2009; 62:1300–1304. [PubMed: 19780183]

98. Dzien P, Tee SS, Kettunen MI, Lyons SK, Larkin TJ, Timm KN, Hu DE, Wright A, Rodrigues TB, Serrao EM. ^{13}C magnetic resonance spectroscopy measurements with hyperpolarized [1- ^{13}C] pyruvate can be used to detect the expression of transgenic pyruvate decarboxylase activity in vivo. *Magnetic resonance in medicine*. 2015; 76:391–401. [PubMed: 26388418]
99. Patrick PS, Kettunen MI, Tee SS, Rodrigues TB, Serrao E, Timm KN, McGuire S, Brindle KM. Detection of transgene expression using hyperpolarized ^{13}C urea and diffusion-weighted magnetic resonance spectroscopy. *Magnetic resonance in medicine*. 2015; 73:1401–1406. [PubMed: 24733406]
100. Lee Y, Zeng H, Ruedisser S, Gossert AD, Hilty C. Nuclear magnetic resonance of hyperpolarized fluorine for characterization of protein-ligand interactions. *Journal of the American Chemical Society*. 2012; 134:17448–17451. [PubMed: 23020226]
101. Desai M, Slusarczyk AL, Chapin A, Barch M, Jasanoff A. Molecular imaging with engineered physiology. *Nature Communications*. 2016; 7:13607.
102. Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. *Circulation*. 1991; 83:2038–2047. [PubMed: 2040056]
103. Brain S, Williams T, Tippins J, Morris H, MacIntyre I. Calcitonin gene-related peptide is a potent vasodilator. *Nature*. 1985; 313:54–56. [PubMed: 3917554]
104. Zhang S, Merritt M, Woessner DE, Lenkinski RE, Sherry AD. PARACEST agents: modulating MRI contrast via water proton exchange. *Accounts of chemical research*. 2003; 36:783–790. [PubMed: 14567712]
105. Dorazio SJ, Tsitovich PB, Sifers KE, Sperryak JA, Morrow JR. Iron (II) paraCEST MRI contrast agents. *Journal of the American Chemical Society*. 2011; 133:14154–14156. [PubMed: 21838276]
106. Dorazio SJ, Olatunde AO, Sperryak JA, Morrow JR. CoCEST: cobalt (II) amide-appended paraCEST MRI contrast agents. *Chemical Communications*. 2013; 49:10025–10027. [PubMed: 24045271]
107. Olatunde AO, Dorazio SJ, Sperryak JA, Morrow JR. The NiCEST approach: nickel (II) paraCEST MRI contrast agents. *Journal of the American Chemical Society*. 2012; 134:18503–18505. [PubMed: 23102112]
108. Glöggl S, Colell J, Appelt S. Para-hydrogen perspectives in hyperpolarized NMR. *Journal of Magnetic Resonance*. 2013; 235:130–142. [PubMed: 23932399]
109. Gilad AA, Shapiro MG. Molecular Imaging in Synthetic Biology, and Synthetic Biology in Molecular Imaging. *Molecular Imaging and Biology*. 2017:1–6.
110. Choi, J-s, Kim, S., Yoo, D., Shin, T-H., Kim, H., Gomes, MD., Kim, SH., Pines, A., Cheon, J. Distance-dependent magnetic resonance tuning as a versatile MRI sensing platform for biological targets. *Nature Materials*. 2017; 16:537–542. [PubMed: 28166216]
111. Panagiotopoulos N, Duschka RL, Ahlborg M, Bringout G, Debbeler C, Graeser M, Kaethner C, Lütke-Buzug K, Medimagh H, Stelzner J. Magnetic particle imaging: current developments and future directions. *International journal of nanomedicine*. 2015; 10:3097–3114. [PubMed: 25960650]
112. Saritas EU, Goodwill PW, Croft LR, Konkle JJ, Lu K, Zheng B, Conolly SM. Magnetic particle imaging (MPI) for NMR and MRI researchers. *Journal of Magnetic Resonance*. 2013; 229:116–126. [PubMed: 23305842]
113. Shapiro MG, Goodwill PW, Neogy A, Yin M, Foster FS, Schaffer DV, Conolly SM. Biogenic gas nanostructures as ultrasonic molecular reporters. *Nature nanotechnology*. 2014; 9:311–316.
114. Iordanova B, Ahrens ET. In vivo magnetic resonance imaging of ferritin-based reporter visualizes native neuroblast migration. *Neuroimage*. 2012; 59:1004–1012. [PubMed: 21939774]
115. Cohen B, Dafni H, Meir G, Harmelin A, Neeman M. Ferritin as an endogenous MRI reporter for noninvasive imaging of gene expression in C6 glioma tumors. *Neoplasia*. 2005; 7:109–117. [PubMed: 15802016]
116. Cohen B, Ziv K, Plaks V, Israely T, Kalchenko V, Harmelin A, Benjamin LE, Neeman M. MRI detection of transcriptional regulation of gene expression in transgenic mice. *Nature medicine*. 2007; 13:498–503.

117. Gries H, Krause W. Contrast Agents I: Magnetic Resonance Imaging. 2002

Glossary

ADC	Apparent Diffusion Coefficient
AQP1	Aquaporin 1
BOLD	Blood Oxygenation Level Dependent
CEST	Chemical Exchange Saturation Transfer
CGRP	Calcitonin Gene Related Peptide
CNR	Contrast-to-Noise Ratio
DNP	Dynamic Nuclear Polarization
DWI	Diffusion Weighted Imaging
FEXI	Filter Exchange Imaging
FRET	Förster Resonance Energy Transfer
GV	Gas Vesicle
HyperCEST	Hyperpolarized Chemical Exchange Saturation Transfer
MPI	Magnetic Particle Imaging
MRET	Magnetic Resonance Energy Transfer
MRI	Magnetic Resonance Imaging
ParaCEST	Paramagnetic Chemical Exchange Saturation Transfer
PHIP	Parahydrogen Induced Polarization
SNR	Signal-to-Noise Ratio
UT-B	Urea Transporter

Highlights

- Biomolecular reporters are essential to enable MR imaging of cellular function
- Several breakthrough concepts in biomolecular MRI reporters were recently developed
- Water channel proteins serve as reporter genes for diffusion-weighted imaging
- Gas-filled proteins produce contrast in hyperpolarized ^{129}Xe MRI
- Peptides altering blood flow produce locally enhanced hemodynamic contrast




Figure 1. Mechanisms of Biomolecular MRI Contrast

(a) T₁ reporters include proteins containing paramagnetic metal ions such as iron or manganese. (b) T₂ reporters include proteins biomineralizing iron oxide nanoparticles. (c) CEST reporters include proteins with large numbers of exchangeable protons. (d) Accumulation and activation-based reporters transport, trap or catalytically activate exogenous contrast agents. (e) Diffusion based reporters are proteins that facilitate the exchange of water across the cell membrane. (f) HyperCEST reporters contain chemically distinct binding sites for xenon. (g) Hemodynamic reporters act on the vasculature to increase local blood flow.




Figure 2. Diffusion-based Reporters

(a) Diffusion weighted images of mammalian cells expressing AQP1 and GFP (negative control) acquired using $\Delta_{eff} = 298$ ms and b-values of 2089 s/mm^2 (CHO), 1000 s/mm^2 (U87), and 800 s/mm^2 (N2a) (b) *Left*: Experimental approach for establishing bilateral tumor xenografts, inducing transgene expression with doxycycline (dox), and acquiring diffusion-weighted images. *Right*: Representative diffusion weighted image of a horizontal section of the mouse brain 48 hours after dox injection. Inset shows a diffusion weighted image of the same mouse brain prior to dox induction. Images were acquired using $\Delta_{eff} = 98$ ms and $b = 1000$ s/mm^2 (c) Monte Carlo simulations of water diffusion in cells show an increase in apparent diffusion coefficient (ADC) with increasing cell membrane permeability and at long diffusion times (Δ_{eff}) that is achieved using stimulated echo DWI (d) Increase in ADC in CHO, U87, and N2a cells relative to control cells expressing GFP, measured at $\Delta_{eff} = 398$ ms. Adapted with permission from [56].




Figure 3. HyperCEST Reporters

(a) Diagram of a gas vesicle: a hollow gas-containing nano-compartment (solid shading) surrounded by a gas-permeable protein shell (ribbed shading). (b) Transmission electron micrographs of individual GVs purified from *Halobacterium* NRC-1 in their intact (left) and collapsed (right) state. (c) Diagram of ¹²⁹Xe chemical exchange saturation transfer between bulk aqueous solvent (left) and GVs (hexagons) either in isolation or inside a cell (gray). (d) Frequency-dependent saturation spectra for intact (red) and collapsed (black) GVs. (e)

Saturation contrast image of a three-compartment phantom containing 400pM GVs, 100pM GVs and buffer. Adapted with permission from [92, 113].

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Mechanisms of Biomolecular MRI Contrast

Mechanism	Example	Approximate Detection Limit	Advantages	Disadvantages
T_1	P450-BM3 [9]	14 μ M 700 μ g/mL	Readily engineered as molecular sensors	Metal requirement
T_2	Ferritin [25, 26, 114–116]	84 nM 40 μ g/mL	Relatively sensitive	Metal requirement Background T_2 contrast
CEST	LRP [33]	2.5 μ M 81 μ g/mL (assuming no background CEST)	No metal requirement Multiplexing	Background CEST from proteins in tissue
Accumulation & Activation	TIMD2 [46]	Unknown	Sensitivity due to amplification	Requires exogenous contrast agent Pharmacokinetically limited
Diffusion	AQP1 [56]	500 nM 14 μ g/mL	No metal requirement Autologous	High background in some tissues
HyperCEST	Gas Vesicles [92]	10 pM 4 μ g/mL	Molar sensitivity due to hyperpolarization Multiplexing	Requires hyperpolarized xenon delivery
Hemodynamics	CGRP [101]	10 nM 53 ng/mL	Sensitivity due to amplification Potentially fast kinetics	Background contrast and unknown long-term effects

Table 2

List of variables

S. No.	Variable	Definition
1	S_{bkg}	Background MRI signal in the absence of contrast agent
2	S_{CA}	MRI signal in the presence of a contrast agent
3	$R_{1,CA}$	T_1 relaxation rate in the presence of contrast agent
4	$T_R, T_{R,opt}$	Repetition time, optimal repetition time
5	x_{CA}	Concentration of T_1, T_2 , or CEST agent
6	$R_{2,CA}$	T_2 relaxation rate in the presence of contrast agent
7	$T_E, T_{E,opt}$	Echo time, optimal echo time
8	PTR	Proton transfer ratio

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

List of assumed parameters

S. No.	Variable	Definition	Value
1	$R_{1,bkgr}$	Background T_1 relaxation rate in the absence of contrast agent	0.67 s^{-1}
2	r_{CA}	T_1 or T_2 relaxivity of contrast agent	$1 \text{ mM}^{-1} \text{ s}^{-1}$ (T_1) $3000 \text{ mM}^{-1} \text{ s}^{-1}$ (T_2)
3	$R_{2,bkgr}$	Background T_2 relaxation rate in the absence of contrast agent	20 s^{-1}
4	x_{H_2O}	Concentration of water in tissues	38.5 M
5	n_{CA}	Number of exchangeable protons in CEST agent	200
6	α	Saturation efficiency in CEST imaging	1
7	$k_{CA \rightarrow w}$	Exchange rate of protons from CEST agent to bulk water	1 kHz
8	T_1	Longitudinal relaxation time of water	1.5 s
9	t_{sat}	CEST saturation time	1.5 s